
CHMP Backs Third Use of Bayer’s Nubeqa™ for Advanced Prostate Cancer
CHMP Endorses Darolutamide (Nubeqa™) Plus ADT for Metastatic Hormone‑Sensitive Prostate Cancer in EU CHMP The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the use of darolutamide—an innovative…